Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692172 · ClinicalTrials.gov registry record · Phase 3
Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT00692172 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 175 participants.
The verdict
NCT00692172, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.
Interventions
- DRUG Alefacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2001-12 |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00692172
The ClinicalTrials.gov registry entry for NCT00692172 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alefacept is the first listed.
NCT00692172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00692172 about?
NCT00692172 is a clinical study titled "Open-label Study to Evaluate Safety of Multiple Courses of IM Alefacept During Treatment of Chronic Plaque Psoriasis". An extension study to evaluate safety and tolerability of up to 3 additional courses of IM alefacept in patients with chronic plaque psoriasis who have been previously treated with 1 or 2 courses of IM alefacept.
What is the current status of trial NCT00692172?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2001-12. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00692172?
The interventions under investigation include: Alefacept (DRUG).
Who is sponsoring clinical trial NCT00692172?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.